Primary prevention of chronic non-communicable diseases and acetylsalicylic acid: ambiguity of opinions
https://doi.org/10.18087/cardio.2020.3.n928
Abstract
Chronic noninfectious diseases (cardiovascular, bronchopulmonary, oncological diseases and diabetes mellitus) are presently the most common cause of death worldwide, with cardiovascular diseases (CVD) being predominant. For this reason, the key goal of a physician is not only to treat but also to prevent diseases. Acetylsalicylic acid (ASA) is considered one of the most effective drugs for secondary prevention of CVD. However, the use of ASA for primary prevention is still debated. Results of many studies of ASA are inconsistent. Some studies have suggested that using ASA in patients aged 40-70 with a high 10-year risk of CVD and a low risk of bleeding may reduce the incidence of CVD. Administration of ASA to patients with a high or medium risk of CVD is also considered.
About the Authors
V. N. Larina
Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation
Russian Federation
MD, PhD, professor
Russian Federation
MD, PhD, professor
T. A. Gaydina
Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation
Russian Federation
MD, PhD, associate Professor
Russian Federation
MD, PhD, associate Professor
D. S. Mkrtychev
Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation
Russian Federation
Student
Russian Federation
Student
V. A. Kuznetsova
Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation
Russian Federation
Student, SPIN 8617-4030
Russian Federation
Student, SPIN 8617-4030
Z. V. Snezhko
I.M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
References
1. Shalnova S.A., Drapkina O.M. The Trends of Cardiovascular and Cancer Mortality in Russian Men and Women from 2000 to 2016 years. Rational Pharmacotherapy in Cardiology 201 9;1 5(1 ):77-83. D0I:10.20996/1819-6446-201 9-1 5-1-77-83
2. Wilson, L., Bhatnagar, P., & Townsend, N. Comparing trends in mortality from cardiovascular disease and cancer in the United Kingdom, 1983–2013: joinpoint regression analysis. Population Health Metrics, 2017; 15(1). doi:10.1186/s12963-017-0141-5
3. Health care in Russia, statistical handbook - 2017- Moscow - 1-171 p. ISBN 978-5-89476-448-1
4. Kotseva K. et al. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil 2009; 16(2):121-37. doi: 10.1097/HJR.0b013e3283294b1d
5. Galyavich A.S., Khairullin R. N., Baleeva L.V., Sleiter P., AkimovaS. V., Galimzyanov A.F. et al. Risk factors of coronary artery disease in 27425 outpatients. Russian Journal of Cardiology. 2019;24(6):23-26 http://dx.doi.org/10.15829/1560-4071-2019-6-23-26
6. Balanova Y.A., Shalnova S.A., Imaeva A.E., Kapustina A.V., Muromtseva G.A., Evstifeeva S.E. et al. Prevalence, Awareness, Treatment and Control of Hypertension in Russian Federation (Data of Observational ESSE-RF-2 Study). Rational Pharmacotherapy in Cardiology 2019;15(4):450-466. DOI:10.20996/1819-6446-2019-15-4-450-466
7. Larina Vera N., Kozyrev Sergei E., Nazimkin Kirill E., Saino Olga V., Safarian Sergei L., Gasparian Lilit V. Secondary prevention for non-communicable diseases at out-patient stage: schools of health for patients at municipal polyclinic. СardioSomatics. 2019; 10(2): 49-55. DOI: 10.26442/22217185.2019.2.190297
8. Mekaj, A., Mekaj, Y., & Daci, F. New insights into the mechanisms of action of aspirin and its use in the prevention and treatment of arterial and venous thromboembolism. Therapeutics and Clinical Risk Management, 2015 Sep 24;11:1449-56. doi: 10.2147/TCRM.S92222.
9. Paseban M., Marjaneh R.M. and Banach M. et al. Modulation of microRNAs by aspirin in cardiovascular disease, trends in Cardiovascular Medicine, Trends Cardiovasc Med. 2019 Aug 14. pii: S1050-1738(19)30114-8. doi: 10.1016/j.tcm.2019.08.005.
10. Halvorsen, S., Andreotti, F., ten Berg, J. M., Cattaneo, M., Coccheri, S., Marchioli, R., et al. Aspirin Therapy in Primary Cardiovascular Disease Prevention. Journal of the American College of Cardiology, 2014, 64(3), 319–327. doi:10.1016/j.jacc.2014.03.049
11. Romaine, S. P. R., Tomaszewski, M., Condorelli, G., & Samani, N. J. MicroRNAs in cardiovascular disease: an introduction for clinicians. Heart, 2015, 101(12), 921–928. doi:10.1136/heartjnl-2013-305402
12. ASCEND Study Collaborative Group, Bowman L, Mafham M. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med. 2018;18(16):1529-1539 DOI: 10.1056/NEJMoa1804988
13. García Rodríguez LA, Martín-Pérez M, Hennekens CH, et al. Bleeding risk with long-term low-dose aspirin: a systematic review of observational studies. PLoS ONE. 2016;11:e0160046 doi:10.1371/journal.pone.0160046
14. Piepoli, M. F., Hoes, A. W., Agewall, S., Albus, C., Brotons, C., Catapano, A. L. et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal, 2016, 37(29), 2315–2381. doi:10.1093/eurheartj/ehw106
15. Novikov D.K., Sergeev Yu.V., Novikov P.D., Sergeev A.Yu. Adverse allergic reactions on drugs and other preparations in dermathology. Immunopathology, allergology, infectology 2003, №3: 45-67, ISSN: 2412-320X
16. Luss L.V. Pseudoallergy in clinic. In book: Allergy and immunopathology. Edited by: Poryadin G.V. 1999; 152-166. IBSN: 5-89004-087-1
17. Rossini R., Iorio A.M.A., Pozzi R., Bianco M. Aspirin Desensitization in Patients With Coronary Artery Disease: Results of the Multicenter ADAPTED Registry (Aspirin Desensitization in Patients. JAMA. 2004; 292(24):3017-3023. doi:10.1001/jama.292.24.3017
18. Hermans, M.A., van der Vet, van Hagen, P.M., van Wijk, R.G., van Daele, P.L.A.View. Low frequency of acetyl salicylic acid hypersensitivity in mastocytosis: The results of a double-blind, placebo-controlled challenge study. Allergy. 2018 Oct;73(10):2055-2062. doi: 10.1111/all.13445.
19. Lichtenberger, L. M., & Burge, S. (2018). Aspirin use and the risk of malignant melanoma. Journal of the American Academy of Dermatology. doi:10.1016/j.jaad.2018.07.065
20. Associations between aspirin use and the risk of cancers: a meta-analysis of observational studies Yan Qiao, Tingting Yang, Yong Gan, Wenzhen Li, Chao Wang, Yanhong Gong and Zuxun Lu Qiao et al. BMC Cancer (2018) 18:288 https://doi.org/10.1186/s12885-018-4156-5
21. Meschia, J. F., Bushnell, C., Boden-Albala, B., Braun, L. T., Bravata, D. M., Chaturvedi, S. et al. Guidelines for the Primary Prevention of Stroke. Stroke, 2014, 45(12), 3754–3832. doi:10.1161/str.0000000000000046
22. Bhatt D, Fox K, Harrington R et al. Rationale, Design, and Baseline Characteristics of THEMIS: Effect of Ticagrelor on Health Outcomes in Diabetes Mellitus Patients Intervention Study. Clin Cardiol 2019. Accepted Author Manuscript. DOI:10.1002/clc.23164 8.
23. Okada S, Morimoto T, Ogawa H, Sakuma M, Soejima H, Nakayama M, et al. (2016) Is Long-Term Low-Dose Aspirin Therapy Associated with Renal Dysfunction in Patients with Type 2 Diabetes? JPAD2 Cohort Study. PLoS One. 2016 Jan 25;11(1):e0147635. doi: 10.1371/journal.pone.0147635.
24. Gaziano JM, Brotons C, Coppolecchia R, et al. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebocontrolled trial. Lancet. 2018;392: 1036-46 DOI: 10.1016/S0140-6736(18)31924-X
25. McNeil, J. J., Nelson, M. R., Woods, R. L., Lockery, J. E., Wolfe, R., Reid, C. M., … Murray, A. M. (2018). Effect of Aspirin on All-Cause Mortality in the Healthy Elderly. New England Journal of Medicine. 2018;379(16):1519-1528 doi:10.1056/nejmoa1803955
26. Guirguis-Blake JM, Evans CV, Senger CA, O'Connor EA, Wh itlock EP. Aspirin for the Primary Prevention of Cardiovascular Events: A Systematic Evidence Review for the U.S. Preventive Services Task Force. Ann Intern Med. [Epub ahead of print 12 April 2016] 164:804–813. doi: 10.7326/M15-2113
27. McNeil, J. J., Wolfe, R., Woods, R. L., Tonkin, A. M., Donnan, G. A., Nelson, M. et al. Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly. New England Journal of Medicine. N Engl J Med. 2018; 379:1509-18 doi:10.1056/nejmoa1805819
28. Rothwell et al. (2018). Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials. Lancet. 2018 Aug 4;392(10145):387-399. doi: 10.1016/S0140-6736(18)31133-4.
29. García Rodríguez LA, Martín-Pérez M, Hennekens CH, Rothwell PM, Lanas A (2016) Bleeding Risk with Long-Term Low-Dose Aspirin: A Systematic Review of Observational Studies. PLoS One. 2016 Aug 4;11(8):e0160046. doi: 10.1371/journal.pone.0160046.
30. Bibbins-Domingo K, U.S. Preventive Services Task Force. Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2016 Jun 21;164(12):836-45. doi: 10.7326/M16-0577.
31. Kunadian V, Chan D, Ali H, Wilkinson N, Howe N, McColl E, et al. Antiplatelet therapy in the primary prevention of cardiovascular disease in patients with chronic obstructive pulmonary disease: protocol of a randomised controlled proof-of-concept trial (APPLE COPD-ICON 2). BMJ Open. 2018 May 26;8(5):e020713. DOI: 10.1136/bmjopen-2017-020713
32. Kunadian V, Wilson N, Stocken DD, Ali H, McColl E, et al. Antiplatelet therapy in the primary prevention of cardiovascular disease in patients with chronic obstructive pulmonary disease: a randomised controlled proof-of-concept trial. ERJ Open Res. 2019 Aug 5;5(3). DOI: 10.1183/23120541.00110-2019
Review
For citations:
Larina V.N., Gaydina T.A., Mkrtychev D.S., Kuznetsova V.A., Snezhko Z.V. Primary prevention of chronic non-communicable diseases and acetylsalicylic acid: ambiguity of opinions. Kardiologiia. 2020;60(3):96-101. (In Russ.) https://doi.org/10.18087/cardio.2020.3.n928
Views:
1748
Email this article 
Post a Comment 
